CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.
暂无分享,去创建一个
Manuel Hidalgo | Ming Zhao | Mats O Karlsson | Jing Li | M. Hidalgo | M. Karlsson | S. Baker | Ming Zhao | J. Brahmer | Sharyn D Baker | Julie Brahmer | Jing Li | A. Spitz | Avery Spitz
[1] M. Karlsson,et al. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis , 2002, AAPS PharmSci.
[2] A. Jimeno,et al. Evaluation of gefitinib biological effects in patients with solid tumors amenable to sequential biopsies-Final results. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Hidalgo,et al. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients , 2006, Investigational New Drugs.
[4] E. Raymond,et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Radtke,et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics , 2006, Cancer Chemotherapy and Pharmacology.
[6] B. LaFleur,et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Kevin Carroll,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.
[8] P. Jänne,et al. Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] P. Zbinden,et al. METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS , 2005, Drug Metabolism and Disposition.
[10] R. Perez-soler,et al. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Lesley Seymour,et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.
[12] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[13] B. Lum,et al. A population pharmacokinetic (PK) model for erlotinib (E), a small molecule inhibitor of the epidermal growth factor receptor (EGFR) , 2005 .
[14] P. Jänne,et al. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Jimeno,et al. Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[16] G. S. Miles,et al. Cytochrome P450-dependent metabolism of gefitinib , 2005, Xenobiotica; the fate of foreign compounds in biological systems.
[17] M. Ranson,et al. Pharmacokinetic Drug Interactions of Gefitinib with Rifampicin, Itraconazole and Metoprolol , 2005, Clinical pharmacokinetics.
[18] Manuel Hidalgo,et al. An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors , 2004, Cancer Research.
[19] H. Swaisland,et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[20] C. Clarke,et al. CYP3A5 Genotype and Midazolam Clearance in Australian Patients Receiving Chemotherapy , 2004, Clinical pharmacology and therapeutics.
[21] G. Kéri,et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. , 2004, Molecular pharmacology.
[22] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[23] R. Pazdur,et al. United States Food and Drug Administration Drug Approval Summary , 2004, Clinical Cancer Research.
[24] Mark M. Roden,et al. Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein , 1999, Pharmaceutical Research.
[25] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[26] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Fukuoka,et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] A. Harris,et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Roy S Herbst,et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Verweij,et al. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea , 2002, Clinical pharmacology and therapeutics.
[31] M. Kris,et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] E N Jonsson,et al. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.
[33] D. Shen,et al. First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.
[34] D. Shen,et al. Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.
[35] C. Wandel,et al. Midazolam is metabolized by at least three different cytochrome P450 enzymes. , 1994, British journal of anaesthesia.
[36] T. Kronbach,et al. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.